Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Jen WY, Konopleva M, Pemmaraju N. Cancer 2024;130:2260-2271.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jen WY, Konopleva M, Pemmaraju N. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer 2024;130:2260-2271.
PMID: 38620053